conversion is blocked is unable to metabolize thymidine appreciably by any route, including entry into nucleic acids. This suggests that Neurospora lacks a thymidine phosphorylating enzyme. A second mutation blocks the pathway at the 5-hydroxymethyluracil to 5-formyluracil step, whereas a third prevents utilization of uracil and all compounds preceding it in the pathway. The mutant isolation procedures yielded three other classes of mutations which are proposed to be affecting, respectively, regulation of the thymidine degradative pathway, transport of pyrimidine free bases, and transport of pyrimidine nucleosides.
The use of radioactively labeled thymidine as a means of specifically labeling the deoxyribonucleic acid (DNA) of an organism requires that the organism possess a thymidine phosphorylating enzyme and that it lack enzymes which rapidly degrade thymidine. The latter of these conditions is not met in some organisms, because in autoradiographic studies uniformly labeled 'H-thymidine fails to label specifically the DNA of Acetabularia (6) , Spirogyra (18, 20) , Paramecium aurelia (5) , and Neurospora crassa (3) . In fact, a majority of the label is incorporated into the ribonucleic acid (RNA) fraction. A metabolic pathway by which thymidine could be converted to RNA precursors was demonstrated in N. crassa (12) (13) (14) . By administering 14C-thymidine labeled at various positions in the pyrimidine ring, Fink and Fink showed a pattem of labeling in the nucleic acid fraction similar to that obtained with labeled uridine, that is, 8 to 10 times more label in RNA than in DNA. When thymidine 8H-methyl was administered, no label was found in either the RNA or DNA fraction. These data, supplemented by identification of some of the early products of thymidine degradation, including 5-hydroxymethyluracil (5-HMU), indicated a conversion of thymidine to I Present address: Department of Botany, University of Michigan, Ann Arbor, Michigan 48104. uracil through the stepwise oxidation and ultimate elimination of the methyl group of thymine. A simplified diagram of pyrimidine metabolism, including the thymidine to uracil pathway, is shown in Fig. 1 .
The purpose of the experiments reported here was to isolate mutants of the pathway by which thymidine is converted to an RNA precursor. With these mutants, the steps involved in the salvage pathway were better defined. Finally, mutants so blocked were tested to determine whether they could incorporate thymidine specifically into DNA.
MATERIALS AND METHODS Strains. Wild-type strains 4A and 25a, three pyrimidine mutants, pyr-3 (37301a), pyr-J (H-263a), and pyr-4 (36601a), and one purine mutant (ad-6) were used. The mutants were kindly provided by Mary B. Mitchell from the Neurospora stocks of the California Institute of Technology Division of Biology.
Media and chemicals. All mutant stocks were maintained on the complete medium of Horowitz (16) . The medium used for all mutant isolation procedures (with one exception), growth tests, and crosses was that of Westergaard and Mitchell (21) , with appropriate modifications of carbon source, agar content, and pyrimidine supplement. The Wester; gaard-Mitchell medium, which lacks NH4+ nitrogen, 383 Vol. 100, No. I was chosen for these studies because it permits efficient utilization (as pyrimidine sources) of the intermediates of the thymidine degradative pathway. The normal carbon source of 2% sucrose was replaced by 0.2% sucrose and 1.5% sorbose when colonial growth was desired. Radioactive 2-14C-thymidine (30 mc/mmole) and 2-14C-thymine (45 mc/mmole) were purchased from the New England Nuclear Corp., Boston, Mass. Most nonlabeled pyrimidines were purchased from commercial sources. However, 5-formyluracil was synthesized by the method of Cline et al. (9) , and 5-fluorodeoxyuridine was obtained from R. Duschinsky of Hoffman-La Roche, Inc., Nutly, N.J.
Mutagenesis and filtration enrichment. A 10-ml conidial suspension (4 X 106/ml) of a pyr mutant was added to a petri dish (100 by 15 mm) and placed 7.5 cm beneath an ultraviolet (UV) germicidal lamp for from 30 sec to 2 min. The highest yield of mutants was obtained with a UV exposure giving 50% conidial survival.
For the selection of some mutants, a filtration enrichment procedure was employed (22) . A 2.5-ml portion of the irradiated conidial suspension was inoculated into a 250-ml Erlenmeyer flask containing 50 ml of medium, supplemented with 2 to 3 jamoles of the pyrimidine for which nutritional mutants were desired. The conidia were kept in suspension on a rotary shaker, with periodic filtration through a layer of glass wool whenever mycelia became visible. Seven to eight filtrations over a period of 48 to 72 hr at 25 C gave optimal recovery of mutants among surviving conidia.
Immediately after UV irradiation or after the filtration enrichment procedure, 0.1 to 1.0 ml of conidial suspension was spread onto sorbose plates with 0.5 to 2.0 umoles of pyrimidine supplement. At 25 C, colonies continued to appear on the plates from 3 to 7 days after inoculation. The sorbose plates were scanned each day, and newly appearing colonies were transferred from the agar to complete medium slants.
Mutant selection. In selection of mutants affecting the conversion of thymidine to an RNA precursor, cognizance must be taken of two factors. First, mutations affecting this pathway would not normally be detected since Neurospora can synthesize sufficient pyrimidine de novo for growth. However, by employing a pyr mutant (Fig. 1 ) as a parent strain the organism can be made dependent on pyrimidine salvage pathways. Second, pyr mutant conidia will not grow when early intermediates of the thymidine degradative pathway, thymidine, thymine, 5-HMU, and 5-formyluracil, are the sole pyrimidine sources, even though these compounds are utilized if growth is initiated by the addition of uridine or cytidine. Levels of uridine as low as 0.1 umole/25 ml of liquid medium will permit the utilization of some thymidine (0.1 to 0.2 ;mole) as a pyrimidine source. Five different methods were devised to select for mutations affecting the thymidine to RNA precursor pathway.
(i) The first selection method was based on the fact that conidial colonies of pyr-4 on sorbose plates containing limiting uridine plus excess thymidine (0.008 and 0.08 mm, respectively) were larger than if thymidine were lacking. Irradiated pyr-4 conidia were inoculated onto the double-supplemented plates and were incubated until a majority of the colonies had reached a size that indicated they were using thymidine. At this point the smallest colonies were removed and tested for their ability to use thymidine as a pyrimidine source.
(ii) The second procedure designed to yield mutants able to use thymidine as a sole pyrimidine source consisted of inoculating about 4 X 106 irradiated pyr-4 conidia onto sorbose plates containing only thymidine as a pyrimidine source. The few resulting colonies were isolated.
(iii) The third selection method employed the filtration-enrichment procedure. It was especially useful when derivatives able to use thymidine, thymine, and 5-HMU as sole pyrimidine sources became available by the second method. Irradiated conidia were incubated in filtration-enrichment medium containing thymidine, and the surviving conidia, presumably enriched in mutant conidia unable to use thymidine, were spread onto sorbose plates supplemented with uridine. Resulting colonies were tested to determine whether they carried a mutation which blocked a step in the thymidine to RNA precursor pathway.
(iv) The fourth method is a variation of the above filtration-enrichment procedure, in which mutants which could not utilize uracil were selected specifically. UV-irradiated pyr-l conidia were incubated in uracil-supplemented enrichment medium, and surviving conidia were inoculated onto uridine-supplemented sorbose plates.
(v) Finally, the filtration-enrichment procedure was used to select for mutants which could not utilize uridine but which still could use uracil as a pyrimidine source. Irradiated pyr-l conidia were incubated in Fries filtration medium (4) supplemented with uridine. Uracil is used very poorly on Fries medium, and the 384 J. BACFERiOL. US-2 ULA s'-p gg use of this medium protected against the possibility that mutants which could not utilize uridine as such might be lost because they possessed an adaptive system to convert uridine to uracil. Conidia surviving the filtration step were inoculated onto sorbose plates of Westergaard-Mitchell medium supplemented with uracil.
Growth conditions. Growth responses of mutant strains to various pyrimnidines were measured in terms of the dry weight of mycelia. The mold was cultured for 5 to 6 days at 25 C in 25 ml of medium in 125-ml Erlenmeyer flasks. The first 2 days of growth were stationary, after which the flasks were placed on a shaker for the remainder of the growth period. The mycelial pads were removed, dried overnight at 70 C, and weighed. Under these conditions, dry weights were reproducible to 10%.
RNA and DNA extraction. An adaptation of the perchloric acid extraction procedure of Ogur and Rosen (19) was used for extraction of RNA and DNA components. Growth medium was removed from the fresh mycelia by rinsing with water and by gentle suction in a Buchner funnel. Alcohol-and ethersoluble substances were extracted by three changes each of absolute ethyl alcohol, a 1:1 (v/v) mixture of absolute ethyl alcohol and ethyl ether, and ether. Approximately 20 parts of solvent per gram of mold (wet weight) was used in each solvent change. The ether-dry pad was then ground in cold 1.0 M HClO4 (1.0 ml per 50 mg of mycelial dry weight) and allowed to stand for 12 hr at 0 C. The mixture was then centrifuged and the supernatant fluid was removed; the residue was extracted with cold HC1O4 in the same way five more times. The cold HClO4 extract contained essentially all of the RNA in a partially degraded form. The residue from the RNA extraction was extracted three times at 75 C for 15 min with 1.0-ml portions of 1.0 M HClO4. This treatment partially degraded and made soluble all of the DNA. The reliability both of the extraction procedure in separating RNA and DNA and of the calculation of nucleic acid concentration from the UV absorption ( Thymidine, thymine, and 5-HMU were also distinguished by one-dimensional paper chromatography (Whatman no. 1) by using the following three solvent systems: water (100), ethyl acetate-formic acid-water (70:20: 10), and t-butanol-methyl ethyl ketone-waterconcentrated NH4OH (40:30:20:10).
RESULTS
Mutant isolation and genetics. The mutant selection procedures described yielded six classes of mutants which were given the designation uracil (uc) or uridine (ud). When a selection procedure yielded more than one mutant of a given class, only one was chosen for further work. The six representative mutants and their isolation numbers are uc-i (RW-57), uc-2 (RW-135), uc-3 (RW-203), uc-4 (RW-341), uc-S (RW-399), and ud-i (RW-433). Each mutant isolate was crossed to wild type, and dissection of 10 to 20 ordered asci was carried out for each cross. All asci were consistent with a 2:2 segregation of the new mutations among the spore pairs. Recombinants carrying uc or ud mutations in an otherwise wild-type background behaved as prototrophs. This is consistent with the hypothesis that pyrimidine salvage pathways are nonessential to growth. Segregants carrying the new mutations were selected from the crosses, and these were used in all further studies.
The genetic map position of the six mutations remains to be determined, but the following linkage relationships are known: uc-i to pyr-4 on chromosome II, uc-2 and uc-4 to mating type on chromosome I, and uc-5 to pyr-i on chromosome IV. Uc-3 and ud-i have not been assigned to a linkage group. It is evident that the mutations affecting pyrimidine salvage are not clustered on the genetic map.
Characterization of mutants of the thymidine salvage pathway. The uc-i mutation (obtained by the second selection method) when introduced into a pyr-4 strain allowed the utilization of thymidine, thymine, 5-HMU, and 5-formyluracil as sole pyrimidine sources, whereas in the absence of uc-i these compounds could only be used after uridine or cytidine had initiated growth. (Table 1 shows sparing action of thymidine, thymine, and 5-HMU for uridine. Identical results are obtained if cytidine replaces uridine.) Although the regulatory nature of the uc-i mutation in no way altered the distribution of administered 2-14C-thymidine or 2-_4C-thymine (90% of nucleic acid label in RNA, 10% in DNA), the pyr-4 uc-i double mutant was very useful as a parent strain for the selection of mutants in which the thymidine degradative pathway is blocked.
The uc-2 mutation (obtained by the first and VOL. 100, 1969 third selection methods) allows all of the proposed intermediates of the thymidine degradative pathway to be used except the initial compound, thymidine (Table 1 ). It is proposed that the uc-2 mutation blocks the first step of the pathway, cleavage of the deoxyribose sugar from the thymine moiety, through formation of a defective nucleosidase enzyme. The nucleosidase is thought to be specific for all pyrimidine deoxyribonucleosides since, in contrast to the parent pyr-4 uc-l strain, the pyr-4 uc-1 uc-2 mutant cannot utilize deoxyuridine, deoxycytidine, or thymidine (Table  1) . Further, the growth inhibition caused by a Uridine + thymidine.. 42 48 14 13 Uridine + thymine 39 45 fourth pyrimidine deoxyribonucleoside, 5-fluorodeoxyuridine (5-FUdR), is of much longer duration in strains carrying uc-2 than in those lacking it, indicating that uc-2 prevents the breakdown of 5-FUdR. The uc-2 mutation does not affect the utilization of purine deoxyribonucleoside since the growth of an ad-6 uc-2 mutant was good on deoxyadenosine as a purine source.
When thymidine and uridine are administered to a pyr-4 uc-2 double mutant, the majority of the thymidine remains in the growth medium ( Table  2 ). This is in contrast to the removal of all thymidine from the medium that a pyr-4 mutant effects under similar growth conditions. The uc-3 mutation (obtained by the third selection method) prevents the utilization of the first three proposed intermediates of the thymidine degradative pathway, thymidine, thymine, and 5-HMU ( Table 1 ). The fact that the use of 5-formyluracil and uracil is unhindered leads to the conclusion that the uc-3 mutation causes a defective enzyme required in the 5-HMU to 5-formyluracil conversion. That uc-3-carrying strains can partially metabolize thymidine was made clear when the used medium of a uc-3 mutant grown in the presence of thymidine was found to support the growth of a pyr-4 uc-l uc-2 triple mutant. This accumulated product was found to be thymine (Table 2 ). Wild type removes thymidine from the medium as rapidly as does uc-3, but excretes very little thymine. Curiously, no 5-HMU was found in the used medium of uc-3 (nor in the used medium of wild type) incubated with thymidine. It should be reemphasized here that uc and ud mutants grow well on minimal medium in the absence of a pyr mutation. Since the uc-3 mutant is a prototroph, the addition of uridine or cytidine is not required to initiate the growth necessary for the functioning of the thymidine degradative pathway.
The uc-4 mutation (obtained by the fourth selection method) prevents the utilization of thymidine, thymine, 5-HMU, 5-formyluracil, and uracil as pyrimidine sources for the pyr-J uc-4 mutant (Table 3) . This is true even if growth is initiated by small amounts of uridine. On the basis of growth data, the uc-4 mutation can be assigned to blocking a step involved in the conversion of uracil to uridylic acid. The relatively poor growth of the pyr-l uc-4 mutant on uridine is explained by the fact that half of the uridine administered is excreted into the medium as uracil, which the mutant cannot use. A uc-4 mutant given uridine accumulates uracil in the medium, whereas wild type does not ( Table 2) .
Pyrimidine transport. The procedures used in selection for mutants which could not utilize a given pyrimidine could yield two types of mutants, those defective in enzymes converting the pyrimidine into nucleic acid and those lacking the ability to transport the pyrimidine into the cell. The procedures used here have been used to isolate transport mutants in bacteria (17) . Growth data from two double mutants pyr-l uc-S (fourth selection method) and pyr-l ud-1 (fifth selection method) suggest the simple interpretation that uc-5 and ud-l disrupt pyrimidine transport mechanisms (Table 4 ).
The pyr-J uc-S mutant is unable to utilize any free pyrimidine base (thymine, 5-HMU, 5-formyluracil, and uracil), although it can use the ribose and deoxyribose pyrimidine nucleosides (cytidine, uridine, deoxyuridine, and thymidine) in a normal manner. In an exactly reverse manner, the pyr-1 ud-1 double mutant can use all of the free bases but none of the pyrimidine nucleosides. The hypothesis then is that the uc-S locus controls a transport system for the free base pyrimidines b Uridine supplement here was 2.0 jsmoles/flask. and the ud-l locus controls a system for pyrimidine nucleosides. The unlinked uc-4 and uc-S mutations cause similar growth responses to most pyrimidines, but they can easily be distinguished by growth on thymidine. The uc-4 strains (blocked at the last step of thymidine degradative pathway) cannot utilize thymidine, whereas uc-S strains use the thymidine very efficiently. "4C-pyrimidine incorporation. It has been demonstrated that when Neurospora is grown in the presence of 2-14C-thymidine and 2-_14C-thymine, 90% of the resulting nucleic acid label is recovered in the RNA fraction, and when 14Cl methyl-labeled thymidine is administered no label is found in either RNA or DNA (13, 14) . These facts alone do not prove that Neurospora cannot phosphorylate thymidine and incorporate it directly in DNA. An alternate possibility is that Neurospora may have a thymidine phosphorylating system of low activity which would not be detected because of the rapid conversion of its substrate, thymidine, to compounds which are unavailable for specific incorporation in DNA. To test this possibility, 2-_4C-thymidine and 2-14Cthymine were separately administered to a pyr-4 uc-2 double mutant; the uc-2 mutation, as described previously, blocks the initial step in the degradation of thymidine ( Table 5 ). Both the pyr-4 uc-J double mutant and a control pyr-4 strain convert 60 to 70% of the label originally present as 2-14C-thymine into RNA constituents. The pyr-4 mutant converts the label of 2-'4C-thymidine in a similar manner, but the pyr-4 uc-2 mutant transforms only 10% of the label to RNA, whereas over 75% of the thymidine remains unused in the growth medium. However, the amount of label found in pyr-4 uc-2 DNA was proportionately reduced and the distribution of Per cent of total nucleic acid counts due to DNA.7 8 9 8
Per cent of total nucleic acid that is DNA.9 conidia were inoculated into one flask of each type, and growth was allowed for 90 hr at 25 C. Extraction of the mycelial pads was accomplished as described in Materials and Methods. nucleic acid label remained approximately 90% RNA and 10% DNA. Therefore, under conditions in which the conversion of thymidine to RNA precursors was largely blocked, no evidence for the specific incorporation of thymidine into DNA could be shown. Figure 1 shows a pathway by which the pyrimidine ring of thymidine can be converted to uridylic acid and thus made available for incorporation into RNA and DNA pyrimidines. The order of intermediates in the pathway was based on nutritional tests and accumulation studies with strains carrying uc-2, uc-3, and uc-4 mutations. The hypothesis that the uc-2 mutation causes formation of a defective pyrimidine deoxyribonucleosidase enzyme is similar to the explanation of an Fscherichia coli mutant (11) which had lost the ability to use thymidine, deoxyuridine, and deoxycytidine as carbon sources. This mutant was shown to lack thymidine phosphorylase activity, the enzyme responsible for the cleavage of the deoxy sugar from thymidine.
DISCUSSION
The uc-3 mutation prevents the oxidation of 5-HMU to 5-formyluracil because uc-3-carrying strains utilize the formyl compound but not 5-HMU as a pyrimidine source. However, since a uc-3 mutant administered thymidine accumulates large quantities of thymine and none of the expected 5-HMU, the possibility exists that the uc-3 locus may also control the thymine to 5-HMU conversion. Abbott and co-workers (1, 2) demonstrated the formation of 5-HMU from thymine (thymine-7-hydroxylase) and of 5-formyluracil from 5-HMU by cell-free extracts of Neurospora. The two enzyme activities which have been only partially separated by initial purification steps both require 02 and Fe++, a-ketoglutarate, and ascorbate as cofactors. The uc-3 mutant strain, whether it is found to lack one or both of the two enzyme activities, should prove quite useful in work on the enzymology of thymine methyl group oxidation. From what is known of uracil salvage enzymes in other microorganisms (8, 10) , it is probable that the uc-4 mutation causes an inactive pyrophosphorylase enzyme for the one-step formation of uridine-5'phosphate from uracil. The classification of uc-l as a regulatory gene is based on the fact that strains carrying this mutation can use thymidine, thymine, 5-HMU, and 5-formyluracil as sole pyrimidine sources. These growth responses are interpreted to mean that the enzyme(s) necessary for the conversion of 5-formyluracil to uracil is derepressed (or is present at normal levels but not subject to inhibition) in germinating conidia of uc-l strains. The growth tests provide no clue as to whether enzymatic steps before 5-formyluracil in the pathway are subject to control by the uc-1 gene.
Uracil-5-carboxylic acid (5-CU) could be proposed as an intermediate of the thymidine degradative pathway since it might easily be formed from 5-formyluracil and yield uracil upon loss of CO2. However, growth tests with pyr mutants show this compound, in contrast to the other intermediates, to be used very inefficiently as a pyrimidine source. Furthermore, no mutants were found which accumulated 5-CU, nor were mutant hunts successful in finding strains which could utilize the compound as a pyrimidine source. The role of 5-CU as an intermediate awaits the study of enzymes of the pathway.
The pathway for the conversion of thymidine into an RNA precursor is undoubtedly present or capable of being induced in a large number of other organisms. The possibility of the presence of this pathway should be considered in any experiment in which thymidine is to be used for the specific labeling of DNA.
Data were presented showing that 2-'4C-thymidine administered to a strain carrying the uc-2 mutation did not lead to an increased percentage of label incorporated into the DNA. This sub-stantiates the hypothesis of Fink (13) that Neurospora lacks a thymidine-phosphorylating enzyme.
Grivell and Jackson (15) have been unable to demonstrate thymidine kinase (E.C. 2.7.1.21) activity in Neurospora, Aspergillus, and Saccharomyces. Since a large portion of the thymidine given to strains carrying uc-2 remains unused in the medium, it can be assumed that conversion of thymidine to thymine is the only reaction of significance that thymidine can undergo in Neurospora. The lack of a thymidine-phosphorylating enzyme makes it quite doubtful that a thymidine mutant (possessing a nonfunctioning thymidylate synthetase enzyme and, therefore, dependent for growth upon a secondary synthesis of thymidylic acid) of Neurospora can be isolated.
